Effects of selected anti-tumor-promoting chemicals on metabolic cooperation between Chinese hamster V79 cells.
Many tumor-promoting chemicals inhibit gap junctional communication between cells. We investigated the possibility that antipromoting chemicals may act inversely and enhance gap junctional communication. The V79/metabolic cooperation assay is an in vitro test that measures gap junctional communication indirectly by determining the extent of metabolic cooperation between mutant and wild-type V79 Chinese hamster lung fibroblasts in culture. Six in vivo antipromoters (caffeine, 3-isobutyl-1-methylxanthine (IBMX), phenidone, dibromoacetophenone, tosylphenylalanine chloromethyl ketone (TPCK), and acetic acid) were tested in this assay to assess their effects on metabolic cooperation. Caffeine, IBMX, phenidone, and dibromoacetophenone had no effect on metabolic cooperation, while TPCK slightly inhibited metabolic cooperation in one V79 assay. Acetic acid appeared to facilitate metabolic cooperation. In tests where an antipromoter was combined with the established tumor promoter phorbol 12-myristate 13-acetate (PMA), acetic acid, caffeine, and IBMX counteracted PMA-induced inhibition of metabolic cooperation, while phenidone, dibromoacetophenone, and TPCK had little effect. These results indicate that some antipromoters interfere with the ability of a tumor-promoting chemical to inhibit metabolic cooperation and suggest that alteration of gap junctional communication can be a mechanism of antipromoter action.
Mills
L J
LJ
Science Applications International Corporation, U.S. Environmental Protection Agency, Narragansett, Rhode Island 02882.
Nelson
S M
SM
Malcolm
A R
AR
D015056:1-Methyl-3-isobutylxanthine / Q000494:pharmacology; D000085:Acetates / Q000494:pharmacology; D019342:Acetic Acid; D000098:Acetophenones / Q000494:pharmacology; D000818:Animals; D016588:Anticarcinogenic Agents / Q000494:pharmacology*; D016718:Arachidonic Acid / Q000378:metabolism; D002110:Caffeine / Q000494:pharmacology; D002450:Cell Communication / Q000187:drug effects*; D002478:Cells, Cultured; D006224:Cricetinae; D003412:Cricetulus; D017629:Gap Junctions / Q000187:drug effects*; D016859:Lipoxygenase Inhibitors / Q000494:pharmacology; D009154:Mutation / Q000187:drug effects; D010726:Phosphodiesterase Inhibitors / Q000494:pharmacology; D010741:Phospholipases A / Q000037:antagonists & inhibitors; D011480:Protease Inhibitors / Q000494:pharmacology; D011720:Pyrazoles / Q000494:pharmacology; D014108:Tosylphenylalanyl Chloromethyl Ketone / Q000494:pharmacology
D000085:Acetates; D000098:Acetophenones; D016588:Anticarcinogenic Agents; D016859:Lipoxygenase Inhibitors; D010726:Phosphodiesterase Inhibitors; D011480:Protease Inhibitors; D011720:Pyrazoles; D016718:Arachidonic Acid; D002110:Caffeine; D014108:Tosylphenylalanyl Chloromethyl Ketone; D010741:Phospholipases A; C015429:phenidone; C006821:4-bromophenacyl bromide; D019342:Acetic Acid; D015056:1-Methyl-3-isobutylxanthine